Evidence map›Paper›PMID 42215725›Full record

Reviewnpj antimicrobials and resistance2026

Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.

S Weeks, A Brown, K Doughty, D Armstrong-James, N Bennett, M Birch, A M Borman, M Bromley, R Bryson, M C Fisher and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

S Weeks *School of Medical Sciences, University of Manchester, Manchester, UK.
A Brown *Parliamentary Internship Programme, British Society for Antimicrobial Chemotherapy, Birmingham, UK.
K DoughtyCrop Protection Consultant, Monheim, Germany.
D Armstrong-JamesDepartment of Infectious Diseases, Imperial College, London, UK.
N BennettHouse of Lords, Parliament of the United Kingdom, London, UK.
M BirchF2G Ltd, Cheshire, UK.
A M BormanUKHSA National Mycology Reference Laboratory, Bristol, UK.
M BromleyManchester Fungal Infection Group, Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.
R BrysonRSK ADAS Ltd., Cambridge, UK.
M C FisherDepartment of Infectious Disease Epidemiology, Imperial College, School of Public Health, London, UK.
D FreemanThames Water, Reading, UK.
M GrimmerRSK ADAS Ltd., Cambridge, UK.
J H RexF2G Ltd, Cheshire, UK.
H WestFaculty of Science , University of Nottingham, Sutton Bonington Campus, Leicestershire, UK.
P L WhiteMycology Reference Laboratory, Public Health Wales, Cardiff, UK.
M J BotteryManchester Fungal Infection Group, Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK. michael.bottery@manchester.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/Z515619/1Department of Health and Social Care's Global AMR Innovation Fund (GAMRIF) FR1-57Grand Union Doctoral Training Partnership ES/P000649/1Medical Research Council MR/Y034465/1Wellcome TrustWellcome Trust 320833/Z/24/Z
6 · The paper itself

Abstract

Fungal antimicrobial resistance (fAMR) is accelerating, driven in part by the dual-use of antifungal modes of action in agriculture and medicine, threatening therapy. Addressing this challenge requires a unified One Health response that balances agricultural productivity, economic stability, and human and animal health. By focusing on the United Kingdom's policy approach, we argue that current efforts are constrained by fragmented governance, surveillance and regulation. To resolve this, we propose three policy recommendations: 1. a cross-government fAMR body, 2. mandatory environmental and clinical surveillance, and 3. for fungicide approvals to look beyond crop pathogens and integrate risk assessments for potential hotspots of resistance selection in human fungal pathogens. These measures will safeguard current and future antifungals while providing much-needed regulatory clarity and will be translatable to other national and regional contexts.

Identifiers

PMID42215725
PMCPMC13530254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.